Nektar Therapeutics (NKTR) saw an uptrend of 3.14% in the recent trading with $48.68 being its most recent. The current price level -3.66% lower than the highest price of $50.53 marked by the stock while trading over the past 52-weeks, whereas it is 11168.52% higher than the lowest price of $0.43 the company dropped to over past 52-weeks. The latest news story on NKTR appeared in (PR Newswire) under the title “Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.29 for the stock.
Nektar Therapeutics Earnings – What Happened With NKTR
Coming around sales and income figures on NKTR Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Nektar Therapeutics (NKTR) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 14.26% for net revenue.
NKTR – Nektar Therapeutics Stock Earnings Estimates
The perspective of Nektar Therapeutics (NASDAQ:NKTR)’s current quarter earnings identifies that analysts are in consensus over the estimate of -3.09 for stock’s EPS in the current quarter. Nektar Therapeutics (NKTR) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 14.26% for net revenue. Company’s EPS for the last quarter was -2.65.
Nektar Therapeutics – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 19.02 million. NKTR does have institutional investors; and they hold 45.71% of the stock.
As on 2024-06-30, DEEP TRACK CAPITAL, LP was the top most holder in Nektar Therapeutics (NASDAQ:NKTR) with an ownership of 17.88 million shares of the company or 8.5599 of the stake worth $22.17 million. The filing also reveals BLACKROCK INC. as the second largest holder in the company with a control over 7.2575 of the outstanding shares. Its stake is worth $18.79 million for having 15.16 million shares in hand.
VANGUARD GROUP INC also came holding a key position in the company during the recent quarter and it now holds 6.2097 of the outstanding shares. With this there are now 146.0 institutions which have possession in NKTR’s shares.
